Surico Pier Luigi, Barone Vincenzo, Singh Rohan Bir, Coassin Marco, Blanco Tomas, Dohlman Thomas H, Basu Sayan, Chauhan Sunil K, Dana Reza, Di Zazzo Antonio
Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA 02114, USA; Department of Ophthalmology, Campus Bio-Medico University Hospital, Rome 00128, Italy; Cornea Rare Diseases Center, Fondazione Policlinico Campus Bio-Medico, Rome 00128, Italy.
Department of Ophthalmology, Campus Bio-Medico University Hospital, Rome 00128, Italy; Cornea Rare Diseases Center, Fondazione Policlinico Campus Bio-Medico, Rome 00128, Italy.
Surv Ophthalmol. 2025 May-Jun;70(3):467-479. doi: 10.1016/j.survophthal.2024.07.008. Epub 2024 Aug 7.
We explore the interaction between corneal immunity and mesenchymal stem/stromal cells (MSCs) and their potential in treating corneal and ocular surface disorders. We outline the cornea's immune privilege mechanisms and the immunomodulatory substances involved. In this realm, MSCs are characterized by their immunomodulatory properties and regenerative potential, making them promising for therapeutic application. Therefore, we focus on the role of MSCs in immune-mediated corneal diseases such as dry eye disease, corneal transplantation rejection, limbal stem cell deficiency, and ocular graft-versus-host disease. Preclinical and clinical studies demonstrate MSCs' efficacy in promoting corneal healing and reducing inflammation in these conditions. Overall, we emphasize the potential of MSCs as innovative therapies in ophthalmology, offering promising solutions for managing various ocular surface pathologies.
我们探讨角膜免疫与间充质干/基质细胞(MSCs)之间的相互作用及其在治疗角膜和眼表疾病中的潜力。我们概述了角膜的免疫赦免机制及相关的免疫调节物质。在这一领域,MSCs具有免疫调节特性和再生潜力,使其在治疗应用中颇具前景。因此,我们重点关注MSCs在免疫介导的角膜疾病中的作用,如干眼症、角膜移植排斥反应、角膜缘干细胞缺乏症和眼移植物抗宿主病。临床前和临床研究证明了MSCs在这些情况下促进角膜愈合和减轻炎症方面的疗效。总体而言,我们强调MSCs作为眼科创新疗法的潜力,为管理各种眼表疾病提供了有前景的解决方案。